Cholesterol drug setback casts doubt over multibillion-dollar race - cnbc.com

As reported by CNBC

Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Market Samachar is a news aggregator. This article was originally published by CNBC. Tap the button above to read the full story on their site.

More from Market Samachar